KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Non-Current Assets (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Other Non-Current Assets data on record, last reported at $8.8 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 5.72% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $8.8 million, down 5.72%, while the annual FY2025 figure was $8.8 million, 5.72% down from the prior year.
  • Other Non-Current Assets reached $8.8 million in Q4 2025 per PACB's latest filing, up from $1.8 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $9.3 million in Q4 2024 and bottomed at $65000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $3.9 million, with a median of $3.2 million recorded in 2022.
  • The widest YoY moves for Other Non-Current Assets: up 11947.62% in 2021, down 98.14% in 2021.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.1 million in 2021, then tumbled by 36.72% to $3.2 million in 2022, then fell by 15.52% to $2.7 million in 2023, then skyrocketed by 241.84% to $9.3 million in 2024, then decreased by 5.72% to $8.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $8.8 million in Q4 2025, $1.8 million in Q3 2025, and $9.0 million in Q2 2025.